OREANDA-NEWS. In investigator initiated clinical research commissioned by Sharp, results were obtained in exploratory analysis indicating that Plasmacluster Ion technology reduced the level of airway inflammation in pediatric patients with mild to moderate atopic asthma (FeNO value less than 90).

Sharp commissioned The University of Tokyo Hospital, Clinical Research Support Center, to conduct this research, and provided special Plasmacluster Ion generators for use in the clinical study. Mr. Yasuo Ohashi, Emeritus Professor of The University of Tokyo, and also a Professor on the Faculty of Science and Engineering at Chuo University, assumed responsibility for data analysis and design of the clinical research. In addition, Mr. Toshio Katsunuma, Associate Professor, Department of Pediatrics, The Jikei University Daisan Hospital, served as coordinator of trial sites and was in charge of recruiting subjects as well as testing and measurement.

This clinical study targeted 130 pediatric patients with mild to moderate atopic asthma, In this clinical research study, special Plasmacluster Ion generators producing an ion concentration of 100,000 ions/cm3 were set up in the home in two rooms where the subjects spent long periods of time selected from among the bedroom, living room, and children's room (nursery). Observations were made for eight weeks before and eight weeks after activation of the Plasmacluster Ion generators using the individual randomized crossover double-blind comparison protocol.

This clinical study found that the level of airway inflammation in children with atopic asthma was reduced, and that Plasmacluster Ion technology will contribute to human health in an actual living environment.

Dust mite allergens are one of the major antigens causing asthma. Thus far, Sharp has proven that Plasmacluster Ions have an inhibitory effect against airborne dust mite allergens, which are in dust mite fecal pellets and body fragments, and also went on to elucidate the mechanism underlying the inhibition of these allergens.

In the future, Sharp will push ahead with further development of Plasmacluster Ion technology and continue to prove its efficacy with the aim of creating a healthy environment.

It should also be noted that the details of this clinical study are scheduled to be presented by the research group (Professors Yasuo Ohashi and Toshio Katsunuma) at the 51st Annual Meeting of the Japanese Society of Pediatric Allergy and Clinical Immunology to be held beginning November 8, 2014.